£36 MM MCap
UK-based company developing proprietary next-gen antibodies called Affimers.
Avacta is a new Trout client that is a bit under the radar with limited US-exposure to date. They are a bit small/early but we have been getting interest so far on their approach – similar concept to Ablynx, partnership with Moderna, etc.
Affimers are 10X smaller than traditional antibodies that are easy to format, highly specific, easy to manufacture, multiple routes of administration, etc. – comparable to Ablynx’s nan [more information]